Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial

Fengrui Xu; Yang Zhang; Zhanhui Miao; Xiaohua Zeng; Biao Wu; Li Cai; Jinping Liu; Shusen Wang; Xichun Hu; Wenbo Zheng; Zhiyue Chen; Qing Yang; Zefei Jiang

doi:10.21037/atm.2019.07.95

Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial

Annals of Translational Medicine ◽

10.21037/atm.2019.07.95 ◽

2019 ◽

Vol 7 (18) ◽

pp. 482-482 ◽

Cited By ~ 1

Author(s):

Fengrui Xu ◽

Yang Zhang ◽

Zhanhui Miao ◽

Xiaohua Zeng ◽

Biao Wu ◽

...

Keyword(s):

Breast Cancer ◽

Phase Iii ◽

Efficacy And Safety ◽

Phase Iii Trial ◽

Chemotherapy Induced Neutropenia

Download Full-text

Erratum to efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial

Annals of Translational Medicine ◽

10.21037/atm-2020-23 ◽

2020 ◽

Vol 8 (10) ◽

pp. 660-660

Author(s):

Fengrui Xu ◽

Yang Zhang ◽

Zhanhui Miao ◽

Xiaohua Zeng ◽

Biao Wu ◽

...

Keyword(s):

Breast Cancer ◽

Phase Iii ◽

Efficacy And Safety ◽

Phase Iii Trial ◽

Chemotherapy Induced Neutropenia

Download Full-text

Abstract OT1-02-04: SWOG S1418/NRG -BR006: A randomized, phase III trial to evaluate the efficacy and safety of MK-3475 as adjuvant therapy for triple receptor-negative breast cancer with > 1 cm residual invasive cancer or positive lymph nodes (>pN1mic) after neoadjuvant chemotherapy

10.1158/1538-7445.sabcs17-ot1-02-04 ◽

2018 ◽

Author(s):

L Pusztai ◽

WE Barlow ◽

PA Ganz ◽

NL Henry ◽

J White ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Adjuvant Therapy ◽

Lymph Nodes ◽

Invasive Cancer ◽

Phase Iii ◽

Efficacy And Safety ◽

Phase Iii Trial ◽

Positive Lymph Nodes

Download Full-text

PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)

Annals of Oncology ◽

10.1093/annonc/mdy272.357 ◽

2018 ◽

Vol 29 ◽

pp. viii121 ◽

Cited By ~ 1

Author(s):

S. Loibl ◽

O. Metzger ◽

S.J. Mandrekar ◽

C. Mundhenke ◽

S. Seiler ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Induction Treatment ◽

Efficacy And Safety ◽

Her2 Positive ◽

Open Label ◽

Phase Iii Trial ◽

Hormone Receptor Positive ◽

Open Label Phase

Download Full-text

Efficacy and safety of RGB-02, a proposed biosimilar pegfilgrastim to prevent chemotherapy-induced neutropenia: Results of a randomized, double-blind, phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving docetaxel/doxorubicin

Annals of Oncology ◽

10.1093/annonc/mdx388.033 ◽

2017 ◽

Vol 28 ◽

pp. v555 ◽

Cited By ~ 1

Author(s):

K. Horvat-Karajz ◽

D. Grecea ◽

M. Smakal ◽

A. Illes ◽

Z. Kahan

Keyword(s):

Breast Cancer ◽

Clinical Study ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Chemotherapy Induced Neutropenia

Download Full-text

TEAM II: a randomised, multicentre, prospective, phase III trial investigating neoadjuvant hormonal therapy with exemestane for three versus six months (TEAM IIa) and/or the efficacy and safety of the addition of ibandronate to adjuvant hormonal therapy in post-menopausal women with hormone receptor positive early breast cancer (TEAM IIb)

http://isrctn.org/> ◽

10.1186/isrctn17633610 ◽

2012 ◽

Author(s):

C J H van de Velde

Keyword(s):

Breast Cancer ◽

Hormonal Therapy ◽

Phase Iii ◽

Adjuvant Hormonal Therapy ◽

Efficacy And Safety ◽

Phase Iii Trial ◽

Hormone Receptor Positive ◽

Menopausal Women ◽

Prospective Phase ◽

Post Menopausal

Download Full-text

An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer

Cancer Research and Treatment ◽

10.4143/crt.2016.289 ◽

2017 ◽

Vol 49 (3) ◽

pp. 569-577 ◽

Cited By ~ 31

Author(s):

In Hae Park ◽

Joo Hyuk Sohn ◽

Sung Bae Kim ◽

Keun Seok Lee ◽

Joo Seop Chung ◽

...

Keyword(s):

Breast Cancer ◽

Polymeric Micelle ◽

Phase Iii ◽

Cremophor El ◽

Efficacy And Safety ◽

Open Label ◽

Phase Iii Trial

Download Full-text

179TiP EMERALD: A randomized, open-label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901), a novel oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine therapy for ER+/HER2- advanced breast cancer following CDK4/6 inhibitor therapy

Annals of Oncology ◽

10.1016/j.annonc.2020.03.279 ◽

2020 ◽

Vol 31 ◽

pp. S80

Author(s):

A. Bardia ◽

J. Lu ◽

V. Kaklamani ◽

J. Jung ◽

A.T. Anderson-Villaluz ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Advanced Breast Cancer ◽

Endocrine Therapy ◽

Inhibitor Therapy ◽

Phase Iii ◽

Efficacy And Safety ◽

Open Label ◽

Phase Iii Trial ◽

Open Label Phase

Download Full-text

Abstract P6-17-03: 24 months results from a double-blind, randomized phase III trial comparing the efficacy and safety of neoadjuvant then adjuvant trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early breast cancer (EBC)

10.1158/1538-7445.sabcs18-p6-17-03 ◽

2019 ◽

Author(s):

FJ Esteva ◽

S Lee ◽

S Yu ◽

M Kim ◽

N Kim ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Phase Iii ◽

Efficacy And Safety ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Double Blind ◽

Phase Iii Trial

Download Full-text

3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC)

Annals of Oncology ◽

10.1093/annonc/mdz240.016 ◽

2019 ◽

Vol 30 ◽

pp. v63-v64

Author(s):

J. Stebbing ◽

Y. Baranau ◽

V. Baryash ◽

A. Manikhas ◽

V. Moiseyenko ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Phase Iii ◽

Efficacy And Safety ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Phase Iii Trial

Download Full-text

Abstract OT3-02-07: PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)

10.1158/1538-7445.sabcs18-ot3-02-07 ◽

2019 ◽

Author(s):

O Metzger ◽

S Mandrekar ◽

S Loibl ◽

C Mundhenke ◽

S Seiler ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Induction Treatment ◽

Efficacy And Safety ◽

Her2 Positive ◽

Open Label ◽

Phase Iii Trial ◽

Hormone Receptor Positive ◽

Open Label Phase

Download Full-text